These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26496016)

  • 1. Establishing the cut-off score for remission and severity-ranges on the Psychotic Depression Assessment Scale (PDAS).
    Østergaard SD; Rothschild AJ; Flint AJ; Mulsant BH; Whyte EM; Vermeulen T; Bech P; Meyers BS
    J Affect Disord; 2016 Jan; 190():111-114. PubMed ID: 26496016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring treatment response in psychotic depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account.
    Østergaard SD; Meyers BS; Flint AJ; Mulsant BH; Whyte EM; Ulbricht CM; Bech P; Rothschild AJ;
    J Affect Disord; 2014 May; 160():68-73. PubMed ID: 24439830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD II.
    Flint AJ; Meyers BS; Rothschild AJ; Whyte EM; Mulsant BH; Rudorfer MV; Marino P;
    BMC Psychiatry; 2013 Jan; 13():38. PubMed ID: 23351522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Association of Baseline Suicidality With Treatment Outcome in Psychotic Depression.
    Bingham KS; Rothschild AJ; Mulsant BH; Whyte EM; Meyers BS; Banerjee S; Szanto K; Flint AJ;
    J Clin Psychiatry; 2017; 78(8):1149-1154. PubMed ID: 28445632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial.
    Flint AJ; Meyers BS; Rothschild AJ; Whyte EM; Alexopoulos GS; Rudorfer MV; Marino P; Banerjee S; Pollari CD; Wu Y; Voineskos AN; Mulsant BH;
    JAMA; 2019 Aug; 322(7):622-631. PubMed ID: 31429896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial.
    Blumberger DM; Mulsant BH; Emeremni C; Houck P; Andreescu C; Mazumdar S; Whyte E; Rothschild AJ; Flint AJ; Meyers BS
    J Psychiatr Res; 2011 Jul; 45(7):896-901. PubMed ID: 21300377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship Between Cerebrovascular Risk, Cognition, and Treatment Outcome in Late-Life Psychotic Depression.
    Bingham KS; Whyte EM; Meyers BS; Mulsant BH; Rothschild AJ; Banerjee S; Flint AJ;
    Am J Geriatr Psychiatry; 2015 Dec; 23(12):1270-1275. PubMed ID: 26560512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures.
    Deligiannidis KM; Rothschild AJ; Barton BA; Kroll-Desrosiers AR; Meyers BS; Flint AJ; Whyte EM; Mulsant BH;
    J Clin Psychiatry; 2013 Oct; 74(10):1003-9. PubMed ID: 24229753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the BPRS-5 subscale of the psychotic depression assessment scale a reliable screening tool for psychotic depression?: Results from the CRESCEND study.
    Park SC; Østergaard SD; Choi J; Kim JM; Jun TY; Lee MS; Kim JB; Yim HW; Park YC
    J Affect Disord; 2015 Mar; 174():188-91. PubMed ID: 25506755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stabilization treatment of remitted psychotic depression: the STOP-PD study.
    Bingham KS; Meyers BS; Mulsant BH; Rothschild AJ; Whyte EM; Banerjee S; Artis AS; Alexopoulos GS; Flint AJ;
    Acta Psychiatr Scand; 2018 Sep; 138(3):267-273. PubMed ID: 29959765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the Psychotic Depression Assessment Scale a useful diagnostic tool? The CRESCEND study.
    Park SC; Choi J; Kim JM; Jun TY; Lee MS; Kim JB; Yim HW; Park YC
    J Affect Disord; 2014 Sep; 166():79-85. PubMed ID: 25012413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical validation of the Psychotic Depression Assessment Scale (PDAS) against independent global severity ratings in older adults.
    Vermeulen T; Lemey L; Van Diermen L; Schrijvers D; Madani Y; Sabbe B; Van Den Bossche MJA; van der Mast RC; Østergaard SD
    Acta Neuropsychiatr; 2018 Aug; 30(4):203-208. PubMed ID: 29501075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual or re-emergent impaired insight into delusions following remission is unrelated to later relapse during a randomized clinical trial of continuation pharmacotherapy for psychotic depression - The STOP-PD II Study.
    Song J; Mulsant BH; Sanches M; Alexopoulos GS; Marino P; Meyers BS; Rothschild AJ; Voineskos AN; Whyte EM; Flint AJ; Gerretsen P;
    J Affect Disord; 2023 Mar; 325():29-34. PubMed ID: 36592671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD).
    Meyers BS; Flint AJ; Rothschild AJ; Mulsant BH; Whyte EM; Peasley-Miklus C; Papademetriou E; Leon AC; Heo M;
    Arch Gen Psychiatry; 2009 Aug; 66(8):838-47. PubMed ID: 19652123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression.
    Weissman J; Flint A; Meyers B; Ghosh S; Mulsant B; Rothschild A; Whyte E;
    Psychiatry Res; 2012 May; 197(3):221-6. PubMed ID: 22464991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Investigation of Remission and Relapse of Psychotic Depression Treated with Sertraline plus Olanzapine: The STOP-PD II Study.
    Men X; Marshe V; Elsheikh SS; Alexopoulos GS; Marino P; Meyers BS; Mulsant BH; Rothschild AJ; Voineskos AN; Whyte EM; Kennedy JL; Flint AJ; Müller DJ
    Neuropsychobiology; 2023; 82(3):168-178. PubMed ID: 37015192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study.
    Davies SJ; Mulsant BH; Flint AJ; Meyers BS; Rothschild AJ; Whyte EM; Kirshner MM; Sorisio D; Pollock BG; Bies RR;
    Hum Psychopharmacol; 2016 May; 31(3):252-5. PubMed ID: 27060853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential impact of anxiety symptoms and anxiety disorders on treatment outcome for psychotic depression in the STOP-PD study.
    Davies SJ; Mulsant BH; Flint AJ; Rothschild AJ; Whyte EM; Meyers BS;
    Compr Psychiatry; 2014 Jul; 55(5):1069-76. PubMed ID: 24656524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.